Bullish short-squeeze thesis on ImmunityBio (IBRX) citing ~40% short interest, ~10 days to cover, a cluster of catalysts (NSCLC data, Saudi FDA approval, pending glioblastoma/CAR-NK data), and improving fundamentals.
IBRX — LONG The author argues IBRX is set up for a short squeeze because roughly 40% of the float (~120M shares) is short with ~10 days to cover, rising cost to borrow and stacking FTDs, meaning shorts cannot exit quickly if volume spikes. The stated catalyst is a cluster of news: Jan 13 positive NSCLC data, Jan 14 Saudi FDA approval, and pending glioblastoma and CAR-NK data, with the Chairman promising multiple press releases and a new $24 price target. The author also cites fundamentals as a floor: revenue up 424% YoY to $32.1M on ANKTIVA ramp and $257M cash, which they say removes bankruptcy risk. The stated trigger is a break and hold above $3.00.
IBRX is the perfect setup for an insane short squeeze. We have the perfect squeeze data along with some crazy catalysts, plus it’s actually a great company.
This Reddit post, published January 14, 2026, features u/Bailey-96 discussing IBRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Bailey-96 · Tickers: IBRX